KYTX Kyverna Therapeutics, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$7.48

Period return

-3.03 (-28.83%)

Volume

882.6K

2026-07-21O $7.25 H $7.52 L $7.15 C $7.48MA5 $7.48MA20 $8.44MA60 $8.61MA120 $8.55

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 12.Highin 22 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 15.LowBUY2 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — Point72 Asset Management, L.P.
신규 편입 · 포트폴리오 비중 0.00%
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.00%
2026. 05. 14.LowBUY2 months ago
JP Morgan: Overweight
US analyst rating / recommendation change.
2026. 04. 23.LowBUY3 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2025. 12. 16.LowBUY7 months ago
Wells Fargo: Overweight
US analyst rating / recommendation change.
2025. 12. 05.LowBUY8 months ago
Morgan Stanley: Overweight
US analyst rating / recommendation change.
2025. 10. 30.LowBUY9 months ago
Wells Fargo: Overweight
US analyst rating / recommendation change.
2025. 10. 27.LowBUY9 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $30.4 · 5 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Sector: Healthcare
Industry: Biotechnology
HQ: Emeryville, CA, United States
Fiscal year end: —
Employees: 130
IPO date: —

View details →

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	205,267	$1.93M	0.00%	—	New position
2	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	222,929	$1.92M	0.00%	—	New position
3	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	181,615	$1.57M	0.00%	—	New position
4	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	32,184	$302.53K	0.00%	—	New position

Kyverna Therapeutics, Inc.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 15.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2026. 05. 14.	JP Morgan	—	Maintain	Overweight → Overweight	—	JP Morgan: Overweight
2026. 04. 23.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2025. 12. 16.	Wells Fargo	—	Maintain	Overweight → Overweight	—	Wells Fargo: Overweight
2025. 12. 05.	Morgan Stanley	—	Maintain	Overweight → Overweight	—	Morgan Stanley: Overweight
2025. 10. 30.	Wells Fargo	—	Maintain	Overweight → Overweight	—	Wells Fargo: Overweight